Of the same 84 RA serum samples, 61 (72.6%) reacted with CitPG, 51 (60.7%) reacted with both CitPG and CitCII, and only 23 (27.4%) of the CCP3+ sera were negative for CitPG and/or CitCII (Fig 6B and 6C). The gene discussed is AGBL3; the disease is rheumatoid arthritis.